This conclusion is
corroborated by findings from an earlier study in which five
experienced clinical pharmacology experts categorized 146 drugs
approved in both Canada and the United States between 1996 and
early 2002 by whether the product was of sufficient importance to
have received priority review status or not (Rawson, 2005).